Are PARP inhibitors a new standard of care option for MBC patients?

Bookmark and Share
Published: 18 Jun 2019
Views: 399
Rating:
Save
Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA

Dr Jennifer Litton talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about using PARP inhibitors to treat metastatic breast cancer (MBC) and whether or not they can be considered a new standard of care option.

She explains that, although PARP inhibitors have been shown to be beneficial and could be considered a new standard of care, they are still not curing patients across the board.

This programme has been supported by an unrestricted educational grant from Pfizer.